3E0F80MIntroduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

Administration›Physiological Systems and Anatomical Regions›Introduction
  • Billable / Specific Code
ICD-10-PCS 3E0F80M
CMS Source: FY 2027 ICD-10-PCS dataset. Effective Oct 1, 2026 – Sep 30, 2027.FacebookXLinkedInPrint

3E0F80M is a billable ICD-10-PCS procedure code for Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Chemotherapy.

Code Identity

ICD-10-PCS Code
3E0F80M
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
Short Description
Introduction of Antneo, Moncln Ab, into Resp Tract, Endo
Parent Code
3E0

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1Section3Administration
2Body SystemEPhysiological Systems and Anatomical Regions
3Operation0Introduction
4BodySystem/RegionFRespiratory Tract
5Approach8Via Natural or Artificial Opening Endoscopic
6Substance0Antineoplastic
7QualifierMMonoclonal Antibody

In the ICD-10-PCS Alphabetic Index

These FY 2027 ICD-10-PCS Alphabetic Index entries lead to this code:

Lurbinectedin
Anatomy or device term that leads here
NA-1 (Nerinitide)
Anatomy or device term that leads here
RYBREVANT(tm) infusion
Anatomy or device term that leads here
ZEPZELCA(tm) (Lurbinectedin)
Anatomy or device term that leads here
Amivantamab Monoclonal Antibody
Anatomy or device term that leads here
RYBREVANT (tm) (Amivantamab Monoclonal Antibody)
Anatomy or device term that leads here
Immunotherapy, antineoplastic, Monoclonal antibody
Anatomy or device term that leads here
Introduction of substance in or on, Respiratory Tract
Leads to this code's table
Introduction of substance in or on, Respiratory Tract, Gas
Leads to this code's table
Introduction of substance in or on, Respiratory Tract, Hypnotics
Leads to this code's table
Introduction of substance in or on, Respiratory Tract, Sedatives
Leads to this code's table
Introduction of substance in or on, Respiratory Tract, Analgesics
Leads to this code's table
Introduction of substance in or on, Respiratory Tract, Anti-infective
Leads to this code's table
Introduction of substance in or on, Respiratory Tract, Antineoplastic
Leads to this code's table
Introduction of substance in or on, Respiratory Tract, Anesthetic Agent
Leads to this code's table

Browse the full ICD-10-PCS Alphabetic Index →

Clinical Classification (CCSR)

AHRQ groups this procedure code into these clinical categories.

ADM012
Chemotherapy
Clinical domain: Administration of Therapeutic Substances

Convert to ICD-9-PCS

Closest ICD-9-PCS equivalents for this code under the General Equivalence Mappings.

99.28
Injection or infusion of biological response modifier [BRM] as an antineoplastic agent
Approximate match.

Similar Procedure Codes

Questions About 3E0F80M

Is 3E0F80M a billable code?

Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic on inpatient claims from October 1, 2026 through September 30, 2027.

What do the characters in 3E0F80M mean?

The code breaks down character by character: the 1st character 3 is the Section (Administration); the 2nd character E is the Body System (Physiological Systems and Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character F is the BodySystem/Region (Respiratory Tract); the 5th character 8 is the Approach (Via Natural or Artificial Opening Endoscopic); the 6th character 0 is the Substance (Antineoplastic); the 7th character M is the Qualifier (Monoclonal Antibody).

What is the ICD-9-PCS equivalent of 3E0F80M?

Under the General Equivalence Mappings, Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic crosswalks to ICD-9-PCS 99.28 (Injection or infusion of biological response modifier [BRM] as an antineoplastic agent). The mapping is approximate, so confirm it fits the documentation.